Patents by Inventor Julian NORTHEN

Julian NORTHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYMORPHS OF TRIAZOLE ANTIFUNGAL COMPOUND PC945
    Publication number: 20230028714
    Abstract: The invention relates to crystalline polymorphic manifestations of a compound of formula (I) and related aspects.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 26, 2023
    Applicant: Pulmocide Limited
    Inventors: Christopher John WALLIS, Gerald STEELE, Suzanne BUTTAR, Osama SULEIMAN, Julian NORTHEN, John MYKYTIUK, Jamie MARSHALL
  • CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE
    Publication number: 20220281880
    Abstract: The present invention relates to new crystalline forms of a pyrimido-diazepine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.
    Type: Application
    Filed: August 14, 2020
    Publication date: September 8, 2022
    Inventors: Benjamin SKEAD, Julian NORTHEN, Chris ATHERTON, John MYKYTIUK
  • PKC INHIBITOR SOLID STATE FORMS
    Publication number: 20220048918
    Abstract: The present disclosure relates to various solid state forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine and methods of making the same. Such forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Application
    Filed: July 22, 2021
    Publication date: February 17, 2022
    Inventors: Kay OLMSTEAD, Julian NORTHEN
  • PKC inhibitor solid state forms
    Patent number: 11104679
    Abstract: The present disclosure relates to various solid state forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine and methods of making the same. Such forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: August 31, 2021
    Assignee: MINGSIGHT PHARMACEUTICALS, INC.
    Inventors: Kay Olmstead, Julian Northen
  • NOVEL SALTS
    Publication number: 20200255438
    Abstract: The invention relates to novel salts of 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, to compositions containing said salts and to the use of said salts in treating diseases and conditions mediated by modulation of voltage-gated sodium channels.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 13, 2020
    Inventors: Gerard M. Giblin, David T. MacPherson, Michael Williams, David R. Witty, Julian Northen, Kalyan Vasudevan
  • PKC INHIBITOR SOLID STATE FORMS
    Publication number: 20200223850
    Abstract: The present disclosure relates to various solid state forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine and methods of making the same. Such forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Application
    Filed: May 25, 2018
    Publication date: July 16, 2020
    Inventors: Kay OLMSTEAD, Julian NORTHEN